# SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

> **NCT03065179** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 29 (actual)

## Conditions studied

- Kidney Cancer Metastatic
- Kidney Cancer
- Kidney Cancer, Stage IV

## Interventions

- **DRUG:** Nivolumab/Ipilimumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT03065179
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-11-17
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065179, "SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03065179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*